Centessa Pharmaceuticals plc reported a net loss of $54.9 million for the third quarter of 2025, compared to a loss of $42.6 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $131.4 million, up from $124.4 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $41.6 million in Q3 2025 from $33.9 million in Q3 2024, primarily driven by costs associated with the OX2R agonist program, including clinical study expenses for ORX750 and ORX142. The company reported no license revenue for the quarter, but recognized $15 million in revenue for the nine months due to an upfront payment from a licensing agreement with Genmab.
Centessa's total assets decreased to $448.3 million as of September 30, 2025, down from $576.8 million at the end of 2024. The decline in assets was primarily due to a significant reduction in cash and cash equivalents, which fell to $50.8 million from $383.2 million. The company’s accumulated deficit also increased to $1.12 billion, reflecting ongoing operational losses. The company’s cash, cash equivalents, and investments are expected to fund operations into mid-2027, although it anticipates needing substantial additional funds to advance its product candidates.
In terms of strategic developments, Centessa entered into a licensing agreement with Genmab in February 2025, granting Genmab exclusive rights to utilize its LockBody technology platform for research on three undisclosed targets. This agreement includes potential future milestone payments totaling up to $15 million and royalties on sales of any resulting products. The company is also advancing its pipeline, with ORX750 currently in a Phase 2a clinical trial and ORX142 in a Phase 1 trial, both targeting neurological disorders.
Operationally, Centessa reported an increase in personnel expenses due to a higher headcount, which reached 114 full-time equivalent employees as of October 31, 2025. The company continues to rely on third-party contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for production, which poses risks related to compliance and operational efficiency. The company is also navigating challenges related to geopolitical tensions and inflation, which could impact its supply chain and operational costs.
Looking ahead, Centessa remains focused on advancing its clinical programs and achieving regulatory approvals for its product candidates. However, the company acknowledges the inherent risks and uncertainties in drug development, including potential delays in clinical trials and the need for additional funding. The management emphasizes the importance of maintaining a robust pipeline and effective partnerships to enhance its market position and drive future growth.
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals is a clinical-stage biotech focused on discovering and developing transformative medicines, including orexin receptor 2 (OX2R) agonists for sleep and neurodegenerative disorders, and innovative immuno-oncology therapies using its LockBody platform. It targets neurological, neuropsychiatric, and cancer indications, leveraging proprietary technology and strategic licensing. The company relies on third-party manufacturing, collaborates with partners, and navigates complex regulatory pathways to bring novel treatments to market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.